ROCHESTER, Minn.--(BUSINESS WIRE)--The International Medica Foundation announced today that it has sublicensed to BravoVax Co., Ltd. of China the only rotavirus vaccine (RRV-TV) that has been successfully tested in a large Phase 2 clinical trial to protect neonates from diarrhea caused by rotavirus. The study was completed in Africa in 998 newborns/young infants that received two doses of the RRV-TV vaccine before they were 60 days old. This study demonstrated that only two doses of RRV-TV could provide protection to very young infants well before other commercially available rotavirus vaccines. The RRV-TV vaccine provided protection against rotavirus gastroenteritis comparable in efficacy to three doses of the market leading rotavirus vaccine which is typically given later to older infants leaving them unprotected in their first months of life.
Help employers find you! Check out all the jobs and post your resume.
